Osteoporosis and long-term etretinate therapy.
Whitmore
S E
SE
D005050:Etretinate / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D010024:Osteoporosis / Q000139:chemically induced*; D013997:Time Factors
D007641:Keratolytic Agents; D005050:Etretinate